Stocks · Health care · Pharmaceutical Preparations

Seres Therapeutics, Inc.

MCRB Clue Score46
United States Fiscal year ends December CIK 0001609809 Results filed 4 Nov 2026

What the insiders did Mostly scheduled

Insider
Date
Role
Action
Shares
Price
Amount
Matthew R Henn
15 Feb 2026
See Remarks
Sold after exercise
89
$8.47
$753.83
Thomas DesRosier
15 Feb 2026
See Remarks
Sold after exercise
78
$8.47
$660.66
Teresa L. Young
15 Feb 2026
See Remarks
Sold after exercise
75
$8.47
$635.25
Eric D. Shaff
15 Feb 2026
Director
Sold after exercise
259
$8.47
$2.19K
Matthew R Henn
15 Nov 2025
See Remarks
Sold after exercise
1,257
$17.30
$21.75K
Thomas DesRosier
15 Nov 2025
See Remarks
Sold after exercise
76
$17.30
$1.31K
Eric D. Shaff
15 Nov 2025
Director
Sold after exercise
217
$17.30
$3.75K
Teresa L. Young
15 Nov 2025
See Remarks
Sold after exercise
1,042
$17.30
$18.03K

What was left out

Form 4 filings counted 36
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 7
Sales straight out of an exercise 8
Sales at will 1
Transactions with no price 0
Shares from compensation/vesting 13,636
History held since 29 Jun 2015